We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) announced that the FDA has granted accelerated approval to its antimycobacterial tablets, Sirturo (bedaquiline) as a combination therapy to treat adolescents with pulmonary multidrug-resistant tuberculosis (MDR-TB).
Sirturo is already marketed in combination with a background regimen for treating MDR-TB in adults. Continued approval for the adolescent indication will be based on verification of data from confirmatory studies. A similar application is also under review in the EU.
The approval for Sirturo in adolescents patient group (12 to less than 18 years of age and weighing at least 30 kg) was based on a cohort of a J&J phase II pediatric pharmacokinetic and safety study, C211. The other cohorts of the study are evaluating Sirturo in pediatric patients in different age groups. For the adolescent patient group, the formulation (100 mg tablet) and the dosing recommendation are the same as those approved for adults.
Tuberculosis is a deadly infectious disease, which claimed the lives of 230,000 children in 2017. Though it is more common in adult patients, all age groups are at risk.
J&J’s stock has risen 2.3% this year so far against a decrease of 1.3% recorded by the industry.
Shares of Roche have gained 12.3% this year so far. Earnings estimates for 2019 have risen 0.8% while that for 2020 have increased 2% over the past 30 days.
Sanofi’s earnings estimates have increased 0.3% and 0.9%, respectively, for 2019 and 2020 over the past 30 days.
Merck’s stock is up 11.9% this year so far. Its earnings estimates have risen almost 3% for 2019 and 1.7% for 2020 over the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
J&J's Tuberculosis Drug Gets FDA Nod for Adolescent Patients
Johnson & Johnson (JNJ - Free Report) announced that the FDA has granted accelerated approval to its antimycobacterial tablets, Sirturo (bedaquiline) as a combination therapy to treat adolescents with pulmonary multidrug-resistant tuberculosis (MDR-TB).
Sirturo is already marketed in combination with a background regimen for treating MDR-TB in adults. Continued approval for the adolescent indication will be based on verification of data from confirmatory studies. A similar application is also under review in the EU.
The approval for Sirturo in adolescents patient group (12 to less than 18 years of age and weighing at least 30 kg) was based on a cohort of a J&J phase II pediatric pharmacokinetic and safety study, C211. The other cohorts of the study are evaluating Sirturo in pediatric patients in different age groups. For the adolescent patient group, the formulation (100 mg tablet) and the dosing recommendation are the same as those approved for adults.
Tuberculosis is a deadly infectious disease, which claimed the lives of 230,000 children in 2017. Though it is more common in adult patients, all age groups are at risk.
J&J’s stock has risen 2.3% this year so far against a decrease of 1.3% recorded by the industry.
J&J currently has a Zacks Rank #3 (Hold). Some better-ranked large-cap pharma stocks are Roche Holding AG (RHHBY - Free Report) , Sanofi (SNY - Free Report) and Merck (MRK - Free Report) . While Roche sports a Zacks Rank #1 (Strong Buy), Sanofi and Merck carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Shares of Roche have gained 12.3% this year so far. Earnings estimates for 2019 have risen 0.8% while that for 2020 have increased 2% over the past 30 days.
Sanofi’s earnings estimates have increased 0.3% and 0.9%, respectively, for 2019 and 2020 over the past 30 days.
Merck’s stock is up 11.9% this year so far. Its earnings estimates have risen almost 3% for 2019 and 1.7% for 2020 over the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>